Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: A danish survey

Clinical Cardiology

Volumn 36, Issue 7, 2013, Pages 427-432

  Brandes, Axel ^a   Overgaard, Mikkel ^b   Plauborg, Liane ^b   Dehlendorff, Christian ^e   Lyck, Frede ^c   Peulicke, Jørgen ^d   Poulsen, Søren Vinther ^e   Husted, Steen ^f  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c General Practice ^*  (Denmark)

^d General Practice   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^f REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DENMARK; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DENMARK; DRUG UTILIZATION REVIEW; FEMALE; FIBRINOLYTIC AGENTS; GENERAL PRACTITIONERS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84879838346     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22133     Document Type: Article

References (38)

1. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113: 359-364.
2. Go AS,. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005; 14: 56-61.
3. Dulli DA, Stanko H, Levine RL,. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003; 22: 118-123.
4. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36: 1115-1119.
5. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-1420.
7. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003; 290: 2685-2692.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-1457.
9. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997; 157: 1237-1240.
10. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995; 5: 147-157.
11. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006; 130: 1390-1396.
12. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151: 713-719.
13. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870.
14. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines. Europace. 2006; 8: 651-745.
15. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey On Atrial Fibrillation. Chest. 2010; 137: 263-272.
16. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
17. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an update of the 2010 ESC Guidelines for the Management Of Atrial Fibrillation. Europace. 2012; 14: 1385-1413.
18. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999; 131: 927-934.
19. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123: 638-645. e4
20. Friberg L, Hammar N, Ringh M, et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-Study on Atrial Fibrillation (SCAF-study). Eur Heart J. 2006; 27: 1954-1964.
21. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007; 153: 1006-1012.
22. Dinh T, Nieuwlaat R, Tieleman RG, et al. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands-The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract. 2007; 61: 24-31.
23. Kirchhof P, Nabauer M, Gerth A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost. 2011; 105: 1010-1023.
24. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008; 6: 1500-1506.
25. The FALSTAF Study Group. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. Pharmacoepidemiol Drug Saf. 2007; 16: 32-38.
26. Ruigomez A, Johansson S, Wallander MA, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002; 55: 358-363.
27. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006; 92: 1064-1070.
28. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000; 160: 41-46.
29. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharm. 2004; 57: 798 - 806.
30. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370: 493-503.
31. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349: 1019-1026.
32. Lip GY, Lim HS,. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007; 6: 981-993.
33. Andersen KK, Olsen TS,. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007; 38: 259-263.
34. O'Donnell M, Oczkowski W, Fang J, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006; 5: 749-754.
35. 2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107: 1172-1179.
36. 2 score = 1. Thromb Haemost. 2010; 103: 833-840.
37. Murray S, Lazure P, Pullen C, et al. Atrial fibrillation care: challenges in clinical practice and educational needs assessment. Can J Cardiol. 2011; 27: 98-104.
38. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001; 22: 1852-1923.